BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38479337)

  • 21. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
    Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
    Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
    Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
    J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
    Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
    Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of engagement of FcepsilonRI and CC chemokine receptor 1 on mast cell activation and motility.
    Toda M; Dawson M; Nakamura T; Munro PM; Richardson RM; Bailly M; Ono SJ
    J Biol Chem; 2004 Nov; 279(46):48443-8. PubMed ID: 15337751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
    Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
    Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
    Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
    Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Apoptosis; 2016 Dec; 21(12):1422-1437. PubMed ID: 27734217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
    Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
    Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
    J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma.
    Wang Q; Shi Q; Chen Y; Wang G; Shen L
    Leuk Res; 2023 Apr; 127():107041. PubMed ID: 36801701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 36. Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment.
    Gu X; Wang Z; Pan Q
    J Clin Pharm Ther; 2022 Oct; 47(10):1690-1697. PubMed ID: 36087032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
    Stessman HA; Baughn LB; Sarver A; Xia T; Deshpande R; Mansoor A; Walsh SA; Sunderland JJ; Dolloff NG; Linden MA; Zhan F; Janz S; Myers CL; Van Ness BG
    Mol Cancer Ther; 2013 Jun; 12(6):1140-50. PubMed ID: 23536725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
    Salimi A; Schroeder KM; Schemionek-Reinders M; Vieri M; Maletzke S; Gezer D; Masouleh BK; Appelmann I
    BMC Cancer; 2022 Jul; 22(1):735. PubMed ID: 35790913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13.
    Zhang G; Miao F; Xu J; Wang R
    Bosn J Basic Med Sci; 2020 May; 20(2):209-217. PubMed ID: 31538911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of CCR1 antagonists for multiple myeloma.
    Karash AR; Gilchrist A
    Future Med Chem; 2011 Nov; 3(15):1889-908. PubMed ID: 22023033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.